Sagar Agarwal

IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli et al. · Nature Medicine · 2023 · 119 citations · Full text

Medicine, Dermatology, Immunology +17

Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors.

Alexander Starodub, Ashwin Gollerkeri, Chris De Savi et al. · Journal of Clinical Oncology · 2022 · 23 citations

Medicine, Cancer Biology, Oncology +12

Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Don A. Stevens, Reginald B. Ewesuedo, Alice McDonald et al. · Journal of Clinical Oncology · 2022 · 13 citations

Veterinary Medicine, Cancer Biology, Pathobiology +14